AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2029947
Drug: Clinic school
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic school focusing on high-risk youth and dispensing birth control pills
Trial: 21285532
Drug: Newly-licensed vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly-licensed vaccine (Fluarix™)
Trial: 21285532
Drug: Established vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established vaccine
Trial: 19583486
Drug: Fluoxetine in
RxNorm normalized name: Product containing fluoxetine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine in patients with normal thyroid function (n=15)
Trial: 19583486
Drug: Sertraline in
RxNorm normalized name: Product containing sertraline in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline in patients with normal thyroid function (n=14)
Trial: 19583486
Drug: Fluoxetine in
RxNorm normalized name: Product containing fluoxetine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine in patients with hypothyroidism (n=13)
Trial: 19583486
Drug: Sertraline in
RxNorm normalized name: Product containing sertraline in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline in patients with hypothyroidism (n=15)
Trial: 19583486
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=10) with hypothyroidism on levothyroxine therapy without depression
Trial: 3169222
Drug: Non-treatment (air
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment (air without nebulizer)
Trial: 23453404
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg single dose)
Trial: 23453404
Drug: Everolimus (adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (adjusted doses based on Child‐Pugh classification)
Trial: 23453404
Drug: Thresholds for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thresholds for dose adjustment
Trial: 17121506
Drug: Intervention pharmacists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention pharmacists received video-conference training on the management of depression and provided medication with extra advice and support.
Trial: 15249281
Drug: Melatonin 1
RxNorm normalized name: melatonin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 1 mg nightly for 4 weeks
Trial: 8482063
Drug: NSAID +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID + misoprostol 200 mcg bid
Trial: 3688315
Drug: Trimethoprim (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (200 mg) twice/day for 5 days
Trial: 3688315
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of trimethoprim (600 mg)
Trial: 25882325
Drug: Brexpiprazole 4
RxNorm normalized name: brexpiprazole 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole 4 mg
Trial: 25682550
Drug: Brexpiprazole 1
RxNorm normalized name: brexpiprazole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole 1 mg
Trial: 25882325
Drug: Brexpiprazole 2
RxNorm normalized name: brexpiprazole 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole 2 mg
Trial: 21967319
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of gel mat
Trial: 21967319
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No gel mat
Trial: 16337459
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg once daily
Trial: 15317401
Drug: Subcutaneous fondaparinux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous fondaparinux 2.5 mg once/day
Trial: 9650328
Drug: Acarbose (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (200 mg)
Trial: 9650328
Drug: Plantago psyllium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plantago psyllium mucilage (15 g)
Trial: 7661413
Drug: Continuous nebulization
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nebulization with albuterol (15 mg/hour)
Trial: 7661413
Drug: Metered-dose inhaler
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhaler (MDI) with spacer device delivering albuterol
Trial: 2797066
Drug: Furosemide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (4 ml; 10 mg per milliliter)
Trial: 740584
Drug: Cyclical 'high-dose'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical 'high-dose' oestrogens
Trial: 740584
Drug: Cyclical 'low-dose'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical 'low-dose' oestrogens
Trial: 740584
Drug: Cyclical-sequential oestrogen/progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical-sequential oestrogen/progestogen regimens
Trial: 740584
Drug: Overall hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overall hormonal therapy
Trial: 26069178
Drug: Docetaxel, Cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel, Cisplatin, and 5‐FU (TPF) induction chemotherapy followed by surgery
Trial: 21910821
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (60 units/kg body weight)
Trial: 21910821
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (60 units/kg body weight) with concomitant use of acetylsalicylic acid (ASA)
Trial: 16457909
Drug: HTMV without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HTMV without further DTP doses
Trial: 12629336
Drug: Combination pneumatic/ultrasonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination pneumatic/ultrasonic lithotrite
Trial: 9075663
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (750 mg/day) and endoscopic dilation of major duct stenoses
Trial: 3527809
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg i.v. dose of methylprednisolone sodium succinate (MPSS) followed by an identical dose three hours later in Study Group 2.
Trial: 31654312
Drug: Drospirenone (DRSP)
RxNorm normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drospirenone (DRSP) containing oral contraceptives (3 mg DRSP/30 mcg EE)
Trial: 31654312
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA) containing oral contraceptives (2 mg CMA/30 mcg EE)
Trial: 29502087
Drug: Early intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intervention group attended an antenatal diabetes clinic, commenced daily home blood glucose monitoring, and medication prescribed if lifestyle measures failed.
Trial: 29502087
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with lifestyle education and a 75 g oral glucose tolerance test at 24 weeks' gestation.
Trial: 21999637
Drug: TELEmonitoring device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TELEmonitoring device for medication adherence support used for six months in addition to usual care.
Trial: 21999637
Drug: TELEmonitoring device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TELEmonitoring device for medication adherence support.
Trial: 18488807
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of spironolactone (100 mg)
Trial: 18488807
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of spironolactone (100 mg)
Trial: 18488807
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of canrenone (active metabolite)
Trial: 18488807
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of canrenone (active metabolite)
Trial: 17726806
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 400 micrograms every 4 hours until termination of pregnancy
Trial: 17726806
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 400 micrograms every 4 hours until termination of pregnancy
Trial: 10709412
Drug: Class I
RxNorm normalized name: HLA class I antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class I antiarrhythmic drugs
Trial: 8881094
Drug: Performance-based exposure
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Performance-based exposure treatment
Trial: 8881094
Drug: Combined cognitive/performance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive/performance treatment
Trial: 1555416
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration during apneas
Trial: 29161376
Drug: One-phase treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-phase treatment group (fixed appliance only)
Trial: 29161376
Drug: Two-phase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-phase treatment group (removable appliance before fixed appliance)
Trial: 29071932
Drug: Cobalamin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobalamin (1 mL) injection
Trial: 29071932
Drug: Gangliosides (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gangliosides (1 mL) injection
Trial: 29071932
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication and rehabilitation training (Control)
Trial: 24990160
Drug: Acupuncture (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (12 treatments over 8 weeks, twice weekly for 4 weeks then once weekly for 4 weeks)
Trial: 12728156
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (0.15 mg/kg 6 hourly for 48 hours)
Trial: 7566608
Drug: Daily use
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of analgesic mixtures for at least 5 years
Trial: 31002283
Drug: Heat therapy
RxNorm normalized name: CVS Neck Arm & Leg Heat Therapy Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat therapy (spa bathing at ∼39°C, 3‐5 days/wk for ≤30 min, followed by ≤30 min of callisthenics)
Trial: 23583255
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training plus simvastatin (40 mg/day)
Trial: 21778330
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg daily for 3 months)
Trial: 19801948
Drug: L-asparaginase (L-asp)
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase (L-asp) therapy, median 5.5 doses (range: 1 to 20 doses)
Trial: 19801948
Drug: L-asparaginase (L-asp)
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase (L-asp) therapy
Trial: 19801948
Drug: No L-asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No L-asparaginase therapy (control group)
Trial: 19801948
Drug: High-risk chemotherapy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk chemotherapy regimen
Trial: 11748517
Drug: Nicardipine 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 0.015 mg/kg
Trial: 11748517
Drug: Nicardipine 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 0.03 mg/kg
Trial: 9269506
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy with modified Phleum pratense allergenic extracts
Trial: 9269506
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not treated with specific IT, only drugs)
Trial: 24372434
Drug: Transurethral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral injection of Bulkamid®
Trial: 1662595
Drug: Monthly norethisterone
RxNorm normalized name: ethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly norethisterone enanthate 50 mg + estradiol valerate 5 mg (injectable)
Trial: 7114004
Drug: Indomethacin therapy
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin therapy (n = 13)
Trial: 30703494
Drug: Fufang Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang Danshen Dripping Pill (FDDP)
Trial: 30703494
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clopidogrel and FDDP
Trial: 29663464
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg (30 mg for dose reduction)
Trial: 22005174
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatment (SCT)
Trial: 20599140
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) before therapy sessions
Trial: 15901634
Drug: leflunomide 20
RxNorm normalized name: leflunomide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leflunomide 20 mg daily (n=30)
Trial: 9473540
Drug: Nicardipine (NCR)
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine (NCR) 1/8-2 mg
Trial: 9473540
Drug: Nicardipine (NCR)
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine (NCR) 1/32 mg or more
Trial: 9473540
Drug: Nicardipine (NCR)
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine (NCR) 1/4 mg or less
Trial: 9473540
Drug: Nicardipine (NCR)
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine (NCR) 1/8-1/4 mg
Trial: 7722961
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with insulin
Trial: 25238659
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (leuprolide acetate 1 mg s.c. injection 3 days after ET)
Trial: 25238659
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (two sequential doses of leuprolide acetate 1 mg s.c. injections 3 and 6 days after ET)
Trial: 21813073
Drug: Risperidone treatment
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone treatment (2 to 6 mg/d) for 2 weeks
Trial: 21813073
Drug: Olanzapine treatment
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine treatment (10 to 20 mg/d) for 10 weeks (for nonresponders)
Trial: 21122046
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) treatment for 49 weeks
Trial: 21122046
Drug: Hot wax
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hot wax treatment for 49 weeks
Trial: 19034126
Drug: unpreserved 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unpreserved 0.4% hyaluronic acid eye drops 150 mOsm/L
Trial: 19034126
Drug: unpreserved 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unpreserved 0.4% hyaluronic acid eye drops 300 mOsm/L
Trial: 16025230
Drug: Acute ACE-inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute ACE-inhibitor treatment (< 9 hours after MI)
Trial: 14728070
Drug: trimetazidine MR
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimetazidine MR 35 mg
Trial: 11015815
Drug: Olanzapine 5
RxNorm normalized name: olanzapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5 mg/d
Trial: 19440083
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg/d
Trial: 22776634
Drug: Olanzapine 15
RxNorm normalized name: olanzapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 15 mg/d
Trial: 2647933
Drug: Increased oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased oral cyclosporine dose for 7 to 10 days
Trial: 11287776
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy
Trial: 29157293
Drug: Memantine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (5 mg/day for 48 hours before surgery, increased to 10 mg/day for the first 24 hours after surgery, continued for 3 months)
Trial: 23955138
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus chemotherapy (CTCX group)
Trial: 23955138
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (CT group)
Trial: 19137265
Drug: Acarbose (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (300 mg/day) for 3 months
Trial: 17127704
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of peginterferon alpha‐2a and lamivudine
Trial: 15185991
Drug: Functional training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional training of dysphagia with oral care (once a week for 3 years)
Trial: 15185991
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care (non-training group)
Trial: 15185991
Drug: Functional training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional training of dysphagia with oral care
Trial: 3228824
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both drugs
Trial: 31112386
Drug: Budesonide-Formoterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide-Formoterol (200 μg of budesonide and 6 μg of formoterol, one inhalation as needed)
Trial: 31112386
Drug: Albuterol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (100 μg, two inhalations as needed)
Trial: 31112386
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 μg, one inhalation twice daily) plus as-needed albuterol
Trial: 28859664
Drug: Sequential combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combination of aerobic exercise and cognitive training
Trial: 8978226
Drug: Rehabilitation programmes
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation programmes comprising psychological therapy, counselling, relaxation training, and stress management training over seven weekly group outpatient sessions for patients and spouses.
Trial: 6422914
Drug: High-titer alpha-interferon
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-titer alpha-interferon (100 X 10(6) IU/mL)
Trial: 24731015
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training and review of airway clearance therapy (ACT) for 8 weeks
Trial: 12091679
Drug: 125 mL
RxNorm normalized name: 125 ML argatroban 1 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mL of contrast material at 2.5 mL/sec
Trial: 12091679
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of contrast material at 2.0 mL/sec
Trial: 12091679
Drug: 90 mL
RxNorm normalized name: 190 ML Infugem 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mL of contrast material at 1.5 mL/sec
Trial: 12091679
Drug: 70 mL
RxNorm normalized name: ALCOHOL 70 mL TOPICAL SWAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mL of contrast material at 1.0 mL/sec
Trial: 10069785
Drug: Exercise Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise Training (ET) at 60% of peak VO2, initially 3 times a week for 8 weeks, then twice a week for 1 year